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Proinsulin C-Peptide Prevents Impaired Wound
Healing by Activating Angiogenesis in Diabetes
Young-Cheol Lim1, Mahendra Prasad Bhatt1, Mi-Hye Kwon1, Donghyun Park1, SungHun Na2,
Young-Myeong Kim1 and Kwon-Soo Ha1
Diabetes mellitus disrupts wound repair and leads to the development of chronic wounds, likely due to impaired
angiogenesis. We previously demonstrated that human proinsulin C-peptide can protect against vasculopathy in
diabetes; however, its role in impaired wound healing in diabetes has not been studied. We investigated the
potential roles of C-peptide in protecting against impaired wound healing by inducing angiogenesis using
streptozotocin-induced diabetic mice and human umbilical vein endothelial cells. Diabetes delayed wound
healing in mouse skin, and C-peptide supplement using osmotic pumps significantly increased the rate of skin
wound closure in diabetic mice. Furthermore, C-peptide induced endothelial cell migration and tube formation
in dose-dependent manners, with maximal effect at 0.5 nM. These effects were mediated through activation of
extracellular signal–regulated kinase 1/2 and Akt, as well as nitric oxide formation. C-peptide-enhanced
angiogenesis in vivo was demonstrated by immunohistochemistry and Matrigel plug assays. Our findings
highlight an angiogenic role of C-peptide and its ability to protect against impaired wound healing, which may
have significant implications in reparative and therapeutic angiogenesis in diabetes. Thus, C-peptide replacement
is a promising therapy for impaired angiogenesis and delayed wound healing in diabetes.
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INTRODUCTION
Human proinsulin C-peptide is secreted into circulation in
equimolar concentrations with insulin by pancreatic b-cells
(Ido et al., 1997; Wahren et al., 2007; Hills et al., 2010;
Wahren et al., 2012). C-peptide prevents diabetic complica-
tions, including neuropathy, nephropathy, vascular dysfunc-
tions, and inflammation, in animal models of diabetes and
in type 1 diabetes mellitus (DM) patients (Ido et al., 1997;
Wahren et al., 2007; Hills et al., 2010; Wahren et al., 2012).
In diabetes, increased intracellular reactive oxygen species
levels are recognized as the most common cause of diabetic
vascular complications (Giacco and Brownlee, 2010). We
previously demonstrated that C-peptide can ameliorate endo-
thelial dysfunction through inhibiting intracellular reactive
oxygen species-mediated apoptosis of endothelial cells
by activating AMP-activated protein kinase a (Bhatt et al.,
2013a,b). Recently, we also demonstrated the protective role
of C-peptide against diabetic retinopathy by amelioration
of retinal microvascular leakage (Lim et al., 2013). The multi-
faceted effects of C-peptide in diabetic animals and in
patients are attributed to the activation of multiple cell
signaling pathways, involving p38 mitogen-activated protein
kinase, extracellular signal–regulated kinase 1/2 (ERK1/2), Akt,
and endothelial nitric oxide (NO) production (Kitamura et al.,
2002; Wallerath et al., 2003; Zhong et al., 2005). However,
the mechanism(s) by which C-peptide prevents and/or
ameliorates diabetic complications is not fully understood.
C-peptide deficiency is a typical feature of type 1 DM and
the later stages of type 2 DM (Wahren et al., 2007; Massi-
Benedetti and Orsini-Federici, 2008). DM is one of the major
contributors of impaired wound healing; it leads to apoptosis
and abnormal angiogenesis (Hansen et al., 2003; Graves et al.,
2007). Impaired wound healing can result in diabetic
complications, including chronic open wounds, infections,
and ulcers, and even amputation (Ferringer and Miller, 2002;
Jeffcoate and Harding, 2003; Hirsch et al., 2008). Wound
healing is a dynamic and interactive process involving
angiogenesis, coagulation, inflammation, tissue formation,
and tissue remodeling controlled by growth factors (Li et al.,
2007; Monroe and Hoffman, 2012; Newman and Hughes,
2012). Angiogenesis, the formation of new blood vessels from
preexisting vessels, is a crucial process for wound healing (Sun
et al., 2011). Therefore, understanding the mechanism(s)
involved in the prevention of impaired wound healing is
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necessary to ameliorate diabetic complications (Eming et al.,
2007; Kolluru et al., 2012). C-peptide treatment has been
implicated in the prevention of diabetes complications. How-
ever, the beneficial role of C-peptide in preventing against
impaired wound healing and angiogenesis due to diabetes is
not clear.
In the present study, we aimed to elucidate the physio-
logical functions of C-peptide with regard to impaired wound
healing in diabetes. We hypothesized that C-peptide might
exert a beneficial effect on impaired wound healing by
stimulating angiogenesis and inhibiting inflammation. We
investigated the role of C-peptide in therapeutic angiogenesis
and excisional skin wound repair using streptozotocin-
induced diabetic mice. We further examined the potential
role of C-peptide and its underlying mechanisms in the
process of vascular angiogenesis through the activation of
ERK1/2, Akt, and NO production using human umbilical
vein endothelial cells (HUVECs) in vitro. We assessed neo-
vascularization using the Matrigel plug assay and immuno-
histochemistry. In addition, we demonstrated that C-peptide
normalizes increased inflammatory cytokine levels and
infiltrated inflammatory cells in diabetic mice.
RESULTS
C-peptide prevents impaired wound healing in diabetic mice
To investigate whether C-peptide could normalize impaired
wound healing in diabetic mice, C-peptide was continuously
supplemented using subcutaneously implanted osmotic
pumps in streptozotocin-induced diabetic mice. Wounds of
4-mm diameter were created on the dorsal surface of the
hindlimbs of normal, diabetic, and C-peptide–supplemented
diabetic mice. Diabetic mice exhibited a significantly slower
healing rate compared with normal mice (Figure 1a). How-
ever, C-peptide supplement accelerated wound closure in
diabetic mice. This effect was quantitatively analyzed by
measuring wound diameter (Figure 1b). Wound closure
was much slower in diabetic mice compared with normal
mice (n¼10, Po0.001); however, C-peptide supplementation
attenuated this effect (n¼10, Po0.01). To further study the
C-peptide–mediated stimulation of wound closure, we
analyzed hematoxylin and eosin-stained transverse sections
of the wound beds (Supplementary Figure S1 online). As
suggested by macroscopic observation, wound closure was
dramatically stimulated by C-peptide at 10 days (Figure 1c).
Similar results were obtained by measuring length and area
of hyper-proliferative epithelium at 6 days (Figure 1d,e). Our
results indicate that C-peptide prevents against impaired
wound healing including wound closure in diabetic mice.
C-peptide activation of endothelial cell migration, proliferation,
and tube formation
Because angiogenesis is a crucial process for wound healing
(Sun et al., 2011), we investigated whether C-peptide could
activate endothelial cell migration, proliferation, and tube
formation. C-peptide treatment induced a dose-dependent
increase in endothelial cell chemotactic migration, with a
maximal effect at 0.5 nM (Figure 2a and b). However, heat-
inactivated C-peptide had no effect on endothelial cell
migration (data not shown). C-peptide–induced cell migration
was further investigated with wound-healing assays. C-peptide
(0.5 nM) significantly stimulated cell migration to the wounded
area (Po0.01, Figure 2c and d), with cell proliferation demon-
strated by increase in cell viability (Po0.05, Figure 2e).
As reported previously (Caldwell et al., 2003; Lamalice
et al., 2007), vascular endothelial growth factor (VEGF) also
stimulated chemotactic migration, wound healing, and proli-
feration in endothelial cells (Figures 1 and 2).
Consistent with the cell migration assay results, C-peptide
stimulated tube formation in a dose-dependent manner, with
maximal effect at 0.5 nM (Figure 3a and b). VEGF induced
similar tube formation (Figure 3c). Thus, it was confirmed
that C-peptide activates endothelial cell migration, prolifera-
tion, and tube formation, which are essential for in vitro
angiogenesis.
C-peptide stimulation of angiogenesis through pathways
involving ERK1/2, PI3K/Akt, and NO production
To understand the mechanism by which C-peptide activates
angiogenesis, we investigated the effect of C-peptide on
upstream pathways of angiogenesis, including ERK1/2 and
Akt phosphorylation and NO production. C-peptide increased
ERK1/2 phosphorylation in a time-dependent manner, with
maximal stimulation at 15 minutes, and this ERK1/2 activa-
tion was maintained until 60 minutes (Figure 4a). Similarly,
C-peptide induced time-dependent Akt phosphorylation, with
maximal effect at 15 minutes (Figure 4b). VEGF also induced
ERK1/2 and Akt phosphorylation in a time-dependent manner
(Figure 4a and b). Because Akt phosphorylation increases NO
production via VEGF, which is an important angiogenesis-
mediating factor (Dimmeler et al., 1999), we investigated
whether C-peptide could stimulate NO production (Figure 4c).
Treatment of HUVECs with C-peptide significantly elevated
intracellular NO (Po0.05). A higher level of intracellular
NO was produced with VEGF treatment (Po0.01). These
results suggest that signaling pathways involving ERK1/2, Akt,
and NO production might be involved in C-peptide–induced
angiogenesis.
The roles of ERK1/2, PI3K/Akt, and NO in C-peptide–
induced angiogenesis were examined using PD98059, wort-
mannin, and L-NG-nitroarginine methyl ester (L-NAME),
respectively (Figure 3d). C-peptide–stimulated tube formation
of HUVECs was inhibited by PD98059, the inhibitor of
ERK1/2, in a dose-dependent manner, with maximal inhibi-
tion at 10mM. The PI3K/Akt inhibitor wortmannin and the
NO synthase inhibitor L-NAME also dose dependently inhi-
bited C-peptide–induced tube formation. As expected, VEGF-
induced tube formation was prevented by treatment
with PD98059, wortmannin, or L-NAME (Figure 3e). Our
results indicate that C-peptide stimulates angiogenesis via
signaling pathways involving ERK1/2, PI3K/Akt, and NO
production.
C-peptide activation of blood vessel formation in diabetic mice
To investigate the effect of C-peptide on blood vessel forma-
tion in the wound, the inner surface of dorsal skins from
normal, diabetic, and C-peptide–supplemented diabetic mice
Y-C Lim et al.
C-Peptide and Wound Healing in Diabetes
270 Journal of Investigative Dermatology (2015), Volume 135
was photographed. Blood vessels were obvious in the sub-
cutaneous tissue surrounding the wounds in normal mice but
not in the wound of diabetic mice (Figure 5a). Blood vessel
formation was apparent in C-peptide–supplemented diabetic
mice.
C-peptide–induced blood vessel formation was also inves-
tigated by confocal microscopy of the inner surface of the
dorsal skins from three groups of mice after platelet endothe-
lial cell adhesion molecule-1 (PECAM-1) staining of blood
vessels (Figure 5b). PECAM-1 immunohistochemistry revealed
increased blood vessel formation in normal and C-peptide–
supplemented diabetic mice compared with diabetic mice
(Figure 5b and c), indicating that C-peptide activated blood
vessel formation in the skin of diabetic mice. C-peptide–
induced formation of blood vessels was supported by the
Matrigel plug assay. One week after implantation in C57BL/6
mice, Matrigel containing C-peptide exhibited significantly
greater angiogenesis compared with control, and this result
was similar to that observed following VEGF treatment
(Figure 5d).
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Figure 1. C-peptide prevention against impaired wound healing in diabetic mice. (a, b) Wounds of 4-mm diameter were created on the dorsal skin of the
hindlimbs of normal (n¼ 10), diabetic (n¼ 10), and C-peptide–supplemented diabetic mice (DiabeticþC-peptide; n¼10), and wound closure was
photographically monitored for 14 days. (a) Representative macroscopic images in each group. (b) Wound area was determined by measuring the diameter of
open wounds. (c–e) Hematoxylin and eosin (H&E)-stained transverse sections of the wounds (n¼ 6) were observed at the indicated time using an inverted
microscope. Endpoints are 10, 20, and 12 days for normal, diabetic, and C-peptide–supplemented diabetic mice, respectively. (c) Wound diameter was calculated
using the distance of open wounds. (d, e) Length and area of hyper-proliferative epithelium were measured histologically from the images (6 days). **Po0.01.
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C-peptide activation of blood vessel formation was further
confirmed by confocal microscopy of transverse sections of
wound beds after immunohistochemistry with anti-PECAM-1
and a-smooth muscle actin antibodies (Figure 6a). The number
of blood vessels was significantly lower in diabetic mice
compared with normal mice (Po0.01), and this effect was
normalized in C-peptide supplementation (Figure 6a and b),
indicating that C-peptide activates neovascularization in the
wound bed of diabetic mice. Thus, C-peptide normalizes
impaired wound healing by activating angiogenesis in diabetic
mice.
C-peptide inhibition of inflammation in diabetic mice
To investigate C-peptide effect on inflammation in the
wounds, we performed immunohistochemistry on transverse
sections of wound beds from normal (10 days), diabetic (20
days), and C-peptide–supplemented diabetic mice (12 days)
and determined the levels of inflammatory cytokines by
confocal microscopy. Diabetic mice demonstrated signifi-
cantly higher levels of IL-1b, IL-6, and tumor necrosis factor-
a (TNF-a) compared with normal mice, which were norma-
lized by C-peptide supplementation (Po0.01; Figure 6c),
indicating that C-peptide inhibits inflammation in diabetic
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Figure 2. C-peptide activation of endothelial cell migration and proliferation. (a, b) Transwell migration assays; human umbilical vein endothelial cells (HUVECs)
were incubated in the presence of 10 ng ml 1 vascular endothelial growth factor (VEGF) or the indicated concentrations of C-peptide (C-pep). Migrated cells
on the lower surface of the filters were imaged (a) and counted (n¼ 3) (b). Bar¼ 20mm. (c, d) Wound-healing assays; confluent cell layers were wounded
and incubated with 10 ng ml 1 VEGF or 0.5 nM C-pep. Images were obtained by confocal microscopy (c), and cells that migrated to the scratched area were
counted (d) (n¼ 3). Bar¼ 300mm. (e) Cell viability assay; HUVECs were incubated for 24 hours in the presence of 10 ng ml 1 VEGF or 0.5 nM C-pep (n¼ 3).
*Po0.05, **Po0.01; for VEGF or C-pep versus control.
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mice. In addition, C-peptide reversed the increased number of
infiltrated inflammatory cells (CD11b- and Ly6c-positive cells)
in diabetic mice (Po0.05; Figure 6d). Taken together, our data
indicate that C-peptide normalizes impaired wound healing
by activating angiogenesis as well as inhibiting inflammation
in diabetic mice.
DISCUSSION
C-peptide has emerged as a physiologically active peptide for
ameliorating diabetes-induced complications including vascu-
lar dysfunction and inflammation (Ido et al., 1997; Wahren
et al., 2007; Hills et al., 2010; Wahren et al., 2012; Lim et al.,
2013; Bhatt et al., 2013a,b). In this study, we focused on the
potential angiogenic role of C-peptide and its ability to
ameliorate impaired wound healing in diabetes (Figures 5
and 6). Impaired wound healing in diabetes is a serious
complication that leads to systemic infection, ulceration, and
amputation (Werner and Grose, 2003; Nabuurs-Franssen
et al., 2005; Barrientos et al., 2008). Although hyper-
glycemia alone can cause alterations in body homeostasis,
the deficiency or absence of circulating insulin and C-peptide
may contribute to the development and progression of
hyperglycemia-induced complications.
Experiments with wound animal models have demonstrated
that secretion of growth factors and reductions in inflamma-
tory and oxidative responses are underlying mechanisms of
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Figure 3. C-peptide and vascular endothelial growth factor (VEGF) stimulation of tube formation and its inhibition by various inhibitors. (a–c) C-peptide
stimulation of tube formation. (a) Tube formation was imaged by confocal microscopy. Bar¼300mm. (b) Dose-dependent tube formation induced by C-peptide.
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wortmannin, or 2 mM L-NAME. Results are represented as mean±SD of three independent experiments. *Po0.05, **Po0.01; for inhibitors versus C-peptide
or VEGF.
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angiogenic factor treatment (Werner and Grose, 2003).
Granulation tissue formation and enhanced re-epithelializa-
tion are associated with increased angiogenesis and an
increase in fibroblast number (Fadini et al., 2010). Our
results demonstrate the preventive role of C-peptide against
impaired wound healing through stimulating angiogenesis and
inhibiting inflammation in streptozotocin-induced diabetic
mice. There is a report that C-peptide had no effect on
diabetic wound healing; however, this controversy might be
caused by using non-physiological C-peptide concentration
(over 10 nM in plasma) (Langer et al., 2002). C-peptide
replacement therapy has been investigated in animal models
of diabetic neuropathy and nephropathy but not in diabetes-
impaired wound healing. We systemically administered
C-peptide to diabetic mice to investigate the protective role
of C-peptide against diabetes-impaired wound healing. The
most important finding of the present study is that C-peptide–
treated diabetic mice showed significantly improved wound
healing.
We further investigated the underlying mechanisms of
C-peptide protection in the process of vascular angiogenesis
through the activation of ERK1/2, Akt, and NO production;
this effect was demonstrated in parallel with VEGF-induced
angiogenesis. ERK1/2 has a distinct role in tube formation by
endothelial cells and tube structure maintenance during
angiogenesis, whereas NO stimulates endothelial cell prolif-
eration and migration (Yang et al., 2004). We demonstrated
increases in endothelial cell proliferation, migration, and tube
formation following C-peptide treatment, with a maximum
effect observed within its physiological concentration (0.5 nM);
these effects were similar to those observed following VEGF
treatment. In parallel with VEGF, C-peptide also stimulated
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ERK1/2 and Akt phosphorylation and NO production in
endothelial cells. Blocking the ERK1/2, PI3K/Akt, or endo-
thelial NO species pathway using specific inhibitors suppres-
sed in vitro tube formation induced by both C-peptide and
VEGF. Moreover, the in vivo Matrigel plug assay results
demonstrated a significant increase in angiogenesis upon
C-peptide treatment, similar to that induced by VEGF
treatment. Thus, C-peptide has significant VEGF-mimetic
angiogenic potency both in vitro and in vivo.
We investigated whether C-peptide–mediated acceleration
of wound repair was mediated via its effect on wound site.
C-peptide supplementation normalized increased levels of
inflammatory cytokines and CD11b- and Ly6C-positive cells
in the wound bed of diabetic mice. The normal wound-
healing process is initiated by migration of keratinocytes and
fibroblasts. In diabetes, increased inflammatory cytokines,
such as IL-1b, IL-6, and TNF-a, induce impaired wound
healing by suppressing keratinocyte and fibroblast migration
(Xu et al., 2013). C-peptide induced migration of NIH3T3 cells
in vitro (Supplementary Figure S2 online), suggesting that
C-peptide can directly activate fibroblasts for accelerating
wound repair. However, C-peptide did not activate the HaCaT
cell migration (data not shown), indicating that C-peptide may
indirectly reverse diabetes-induced suppression of keratino-
cyte migration through inhibiting inflammatory cytokines.
PECAM-1 immunohistochemistry demonstrated new blood
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vessel formation in the wounded dorsal skin. Blood vessels
from intact vessels and loops of new capillaries gave the
matrix a red granular appearance. Thus, C-peptide has a
beneficial role in preventing diabetes-impaired wound healing
via its effect on anti-inflammation and neovascularization.
In conclusion, our study reveals an angiogenic role of
C-peptide exerted via pathways involving ERK1/2 and Akt
phosphorylation and NO production. C-peptide supplement
therapy improved diabetes-impaired wound healing by
inhibiting inflammation and stimulating angiogenesis. Thus,
C-peptide replacement is a promising therapeutic strategy for
diabetes-impaired wound healing.
MATERIALS AND METHODS
Animals
Six-week-old male C57BL/6 mice were obtained from KOSTECH
(Pyeongtaek, Korea). Mice were maintained in temperature-controlled
clean racks with a 12-hour-light/dark cycle. All experiments
were performed in accordance with the guidelines of the Institutional
Animal Care and Use Ethics Committee of Kangwon National
University.
Diabetic mouse model
Diabetic mice were generated by a single intraperitoneal injection of
streptozotocin (150 mg per kg body weight) as previously described
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(Bhatt et al., 2013a). After 1 week, mice with non-fasting blood
glucose levels greater than 16 mM, polyuria, and glucosuria were
defined as diabetic. Two weeks after the streptozotocin injection, one
group of diabetic mice was subcutaneously implanted with ALZET
mini-osmotic pumps 2004 (DIRECT, Cupertino, CA) containing
C-peptide in phosphate-buffered saline with a delivery rate of
35 pmol kg 1 per minute for 2 weeks. The other diabetic and
normal groups underwent sham operations.
Skin excision wound and quantitative assessment of wound
healing
The dorsal skin of the vertebral column was shaved with Veet cream
before creating a wound. Full-thickness skin wounds, 4 mm in
diameter, were created on the dorsal surface of the hindlimbs with
a biopsy punch, and closure was monitored with a digital camera.
Open-wound size was measured by tracing the wound margin using
a vernier caliper every other day.
Cell culture
HUVECs were isolated from the human umbilical cord vein accord-
ing to the Declaration of Helsinki as previously described (Park et al.,
2009). Cells were grown at 37 1C in a humidified 5% CO2 incubator
in M199 culture media supplemented with 20% fetal bovine
serum, 3 ng ml 1 basic fibroblast growth factor, 5 U ml 1 heparin,
100 U ml 1 penicillin, and 100mg ml 1 streptomycin. For experi-
ments, cells were incubated for 6 hours in low-serum medium (M199
supplemented as above), but with only 1% fetal bovine serum. Cell
viability was accessed by the Cell Counting Kit-8 (Enzo Life Sciences,
Farmingdale, NY).
Transwell migration assay
Migration assays were performed as previously described (Lee et al.,
2006). Briefly, HUVEC chemotactic motility was assayed using
Transwell Permeable Supports (Costar, Corning, NY). The lower
surface of the filters was coated with 5ml 2% gelatin. Low-serum
media containing VEGF or C-peptide were placed in the lower wells.
HUVECs were seeded in the upper wells in a volume of 200ml low-
serum media containing 1 105 cells per well and incubated at 37 1C
for 12 hours. Cells were fixed with 100% methanol for 15 minutes
and then stained with hematoxylin and eosin. The average number of
migrated cells in three randomly chosen fields per insert was taken
to quantify the extent of migration using a fluorescence inverted
microscope (Olympus, Tokyo, Japan).
Wound-healing assay
Confluent cell layers were starved with low-serum media for 6 hours,
stained with 1mM calcein-AM for 30 minutes, and wounded with
a plastic scraper. Cell debris was removed and replaced with 2 ml
low-serum media containing VEGF or C-peptide. Cells were then
incubated at 37 1C for 24 hours, and the number of migrated cells
was counted from images obtained using a confocal microscope
(FV-300, Olympus).
Tube formation assay
The formation of capillary-like networks by HUVECs on growth
factor–reduced Matrigel (BD Biosciences, Franklin Lakes, NJ) was
achieved as previously described (Namkoong et al., 2009). Briefly,
24-well culture plates were coated with Matrigel according to the
manufacturer’s instructions. HUVECs were seeded onto a layer of
Matrigel at a density of 4 105 cells per well and treated with VEGF
or C-peptide at 37 1C for 24–30 hours. The degree of tube formation
was quantified by measuring tube length from the images using
FV-300 software (Olympus).
Western blot analyses
HUVECs were scraped off with ice-cold lysis buffer (50 mM Tris-HCl,
pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride, 10mg ml 1 aprotinin, and 10mg ml 1
leupeptin) and centrifuged at 18,000g for 10 minutes at 4 1C. The
resulting cell lysates were separated by SDS-PAGE and transferred to
polyvinylidene fluoride membranes. Protein bands were visualized
using a chemiluminescent substrate (Pierce, Rockford, IL).
Measurement of intracellular NO production
Intracellular NO levels were measured using diaminofluorescein-FM
diacetate (Molecular Probes, Eugene, OR) as previously described
(Namkoong et al., 2009). Briefly, HUVECs were treated with VEGF or
C-peptide in phenol red-free low-serum media for the indicated
times and incubated with 2mM diaminofluorescein-FM diacetate for
the final 60 minutes. Intracellular NO levels were determined by
comparing the fluorescence intensities of treated cells with those of
untreated control cells.
Whole-mount immunostaining
Skin tissues were excised using scissors and were immediately fixed
overnight with 4% paraformaldehyde in phosphate-buffered saline.
For immunohistochemistry, tissue samples were blocked with 2%
BSA in tris-buffered saline containing 0.1% Triton X-100 and
incubated with goat-polyclonal PECAM-1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) for 2 days, followed by probing with
Alexa 546-conjugated rabbit anti-goat IgG overnight and observed
under the confocal microscope (FV-300). The length of blood vessel
was determined using FV-300 software (Olympus).
In vivo Matrigel plug assay
In vivo Matrigel plug assays were performed as previously described
(Min et al., 2007). Briefly, mice were injected subcutaneously with
0.5 ml Matrigel containing 100 ng ml 1 VEGF or 5 nM C-peptide and
10 U heparin. After 7 days, the Matrigel plugs were removed from the
subcutaneous region and photographed with a camera (Sony, Tokyo,
Japan).
Histology and immunohistochemistry
Full-skin thickness samples of wound tissue from mice were excised
using scissors, fixed immediately in 4% paraformaldehyde in phos-
phate-buffered saline for overnight, and then embedded in paraffin.
In total, 8-mm paraffin skin sections were cut (Leica, Nussloch,
Germany). Hematoxylin and eosin staining was performed in Harris
hematoxylin solution (Sigma, St Louis, MO) for 5 minutes, followed
by 0.5% eosin (Sigma) for 2 minutes. The wound diameter and hyper-
proliferative epithelium length and area were determined using
FV-300 software (Olympus, Tokyo, Japan).
Immunohistochemistry was performed using goat-polyclonal
PECAM-1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA),
rabbit-polyclonal a-smooth muscle actin and CD11b antibodies
(Santa Cruz Biotechnology), rat-polyclonal Ly6C (BD Biosciences,
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Franklin Lakes, NJ), IL-1b, IL-6, and TNF-a antibodies (Abcam,
Cambridge, MA), followed by probing with Alexa 546-conjugated
rabbit anti-goat IgG, FITC-conjugated goat anti-rabbit IgG, or FITC-
conjugated goat anti-rat IgG for 2 hours, and stained samples were
observed using confocal microscopy (FV-300). The number of blood
vessel and inflammatory cells was counted and the level of inflam-
matory cytokines was determined from the images.
Statistical analysis
Data processing was performed using Origin 6.1 (OriginLab,
Northampton, MA). Statistical significance was determined using
Student’s t-tests and analysis of variance. A P-value less than 0.05
was considered statistically significant.
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